PMID- 33414909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 14
IP  - 2
DP  - 2021 Feb
TI  - Relationship between adverse events associated with lenvatinib treatment for 
      thyroid cancer and patient prognosis.
PG  - 28
LID - 10.3892/mco.2020.2190 [doi]
LID - 28
AB  - Tyrosine kinase inhibitors (TKIs) were first approved for treating radioactive 
      iodine-refractory differentiated thyroid cancer (DTC) and anaplastic thyroid 
      cancer (ATC) 5 years ago. Among them, lenvatinib has a high response rate and has 
      become the first-line drug for treating thyroid cancer. Although it has a high 
      response rate, it is also characterized by a high frequency of adverse events 
      (AEs). AEs previously reported in a phase II study occurred after the practical 
      application of TKI therapy. However, the type and frequency of AEs that occurred 
      were significantly different. The present study investigated the type and 
      frequency of AEs in the real-world setting and examined their relationship with 
      prognosis. Between June 2015 and May 2020, 111 patients (79 patients with DTC and 
      32 patients with ATC) were treated with lenvatinib. An investigation of 
      lenvatinib AEs, including fatal events, revealed that fistula formation or severe 
      tumor regrowth after the discontinuation of treatment was an AE associated with 
      poor prognosis. In total, 11 patients with ATC (34.4%) and 7 patients with DTC 
      (8.9%) developed skin fistula. The mortality rate among these patients was 38.9% 
      (7/18), including three deaths caused by major bleeding and four deaths 
      attributable to mediastinitis or pneumonia. In the DTC group, irreversible 
      regrowth occurred in all 7 patients who required drug withdrawal because of AEs, 
      and all patients died. Conversely, overall survival was longer among patients 
      with DTC and hand-foot syndrome (HFS). Therefore, the present study illustrated 
      that although lenvatinib therapy can result in severe AEs requiring dose 
      reduction or treatment discontinuation, the HFS appearance portends a good 
      prognosis in patients treated with lenvatinib.
CI  - Copyright: (c) Iwasaki et al.
FAU - Iwasaki, Hiroyuki
AU  - Iwasaki H
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Toda, Soji
AU  - Toda S
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Murayama, Daisuke
AU  - Murayama D
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Kato, Shin
AU  - Kato S
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Matsui, Ai
AU  - Matsui A
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC7783723
OTO - NOTNLM
OT  - adverse event
OT  - hand-foot syndrome
OT  - lenvatinib
OT  - prognosis
OT  - retrospective study
OT  - thyroid cancer
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
PMCR- 2020/12/16
CRDT- 2021/01/08 06:11
PHST- 2020/07/02 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2021/01/08 06:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
PHST- 2020/12/16 00:00 [pmc-release]
AID - MCO-0-0-02190 [pii]
AID - 10.3892/mco.2020.2190 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2021 Feb;14(2):28. doi: 10.3892/mco.2020.2190. Epub 2020 Dec 16.